Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases in the United States. The company's lead product candidate, RZ358, is a human monoclonal antibody currently undergoing Phase 2b clinical trials for the treatment of congenital hyperinsulinism, a rare pediatric genetic disorder. Additionally, Rezolute is advancing RZ402, a small molecule plasma kallikrein inhibitor in preclinical development aimed at treating diabetic macular edema. The company was founded in 2010 and is headquartered in Redwood City, California. Rezolute utilizes proprietary formulation and manufacturing capabilities to create innovative therapies that have the potential to enhance existing treatment standards.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
Aviceda Therapeutics is a late-stage, pre-clinical biotechnology company focused on developing innovative treatments for glyco-immune diseases. By leveraging glycobiology and a proprietary cell-based high-throughput screening platform, the company aims to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda's product pipeline includes candidates for a variety of conditions, such as eye diseases, fibrosis, neurology, and oncology. Key products under development include AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 targeting oncology, neurology, and fibrosis. Through its advanced technologies and biological insights, Aviceda seeks to provide breakthrough glycol-therapeutics that improve patient outcomes.
35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics to address diseases with significant unmet medical needs, particularly pulmonary hypertension and musculoskeletal disorders. The company leverages its expertise in protein engineering and a comprehensive understanding of transforming growth factor (TGF)-beta structure-function relationships to create highly effective ligand traps. These advancements aim to facilitate the development of targeted biologics for treating patients suffering from cardio-pulmonary and metabolic diseases.
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.
Inquis Medical is focused on developing innovative thrombectomy technology aimed at enhancing the management of venous thromboembolic diseases. The company's medical devices are designed to address unmet clinical needs while improving the standard of care in this area. Inquis Medical's key offering is an efficient single-pass thrombectomy system that minimizes blood loss, contributing to better patient outcomes. Through its advanced technology, Inquis Medical seeks to provide solutions that have a lasting impact on the treatment of thromboembolic conditions.
Evommune, Inc. is a biotechnology company based in Los Altos, California, that focuses on developing and manufacturing tissue-based medicines aimed at treating inflammatory diseases. Founded in 2020, the company employs a proprietary tissue-based platform to accelerate the discovery of novel therapies, with a particular emphasis on immunology and dermatology. Evommune's approach seeks not only to alleviate the symptoms of inflammatory disorders but also to halt disease progression, thereby improving the quality of life for patients. Its pipeline includes initiatives targeting prevalent inflammatory conditions, with a commitment to advancing patient care by creating best-in-class treatment options. Through innovative strategies, Evommune aims to drive meaningful advancements in the field of inflammatory disease management.
Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.
Pathalys is a clinical biopharmaceutical company that develops therapeutics that improve late-stage chronic kidney disease. Pathalys' initial focus will be on improving treatment for secondary hyperparathyroidism, which is an unmet need (SHPT). SHPT is a condition in which a disease outside of the parathyroid glands causes all of the parathyroid glands to swell and become hyperactive, producing an excessive amount of parathyroid hormone (PTH).
Human Interest is a 401(k) provider that simplifies retirement savings for small and medium-sized businesses. Founded in 2015 in San Francisco by Paul Sawaya and Roger Lee, the company developed an end-to-end technology platform that addresses administrative and compliance challenges associated with retirement plans. This platform automatically creates employee accounts and syncs deductions with payroll providers, ensuring a streamlined process. In addition to facilitating employee retirement accounts, Human Interest offers personalized investment advice, enabling businesses to provide their employees with effective financial security solutions. The company has successfully assisted thousands of businesses across the United States in establishing accessible and affordable retirement plans.
Lycia Therapeutics is a biotechnology firm focused on discovering and developing first-in-class therapies. The company utilizes its innovative lysosomal targeting chimeras (LYTACs) platform to create therapeutics that target and degrade extracellular and membrane-bound proteins associated with challenging diseases, including cancer and autoimmune disorders. By addressing these difficult-to-treat conditions, Lycia Therapeutics aims to provide medical practitioners with effective treatment options to improve patient outcomes.
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
MindMed provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC.
FogPharma is a biotechnology company focused on developing innovative cancer therapies through its unique cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, the company aims to address cancer-causing proteins that are typically inaccessible to traditional treatments. By collaborating with leading experts in cancer biology and therapy, FogPharma is creating a new class of medicines designed to neutralize these challenging targets. The company is supported by a diverse group of private and institutional investors, which enables it to pursue its mission of delivering transformative cancer treatments. FogPharma is dedicated to improving the lives of patients and their families, striving to extend both life expectancy and quality of life.
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease. The company was spun out of Pennsylvania-based Knopp, which published results from its phase 2 clinical trial last year that showed its oral drug candidate could reduce the count of blood eosinophil, which is an indication of improving lung function and is found in several asthma-related treatments.
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments. It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancer patients around the world. It is founded by Bing Yuan, Eric Slosberg, and Andy Fu.
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.
BlueWhale Bio is a spinout from the University of Pennsylvania focused on advancing cell-based therapies through innovative manufacturing techniques. The company develops cell drugs aimed at addressing challenges in gene therapy production, specifically to enhance the effectiveness of cancer treatment. By streamlining the manufacturing process, BlueWhale Bio seeks to facilitate the development of effective cancer treatment plans for patients, ultimately improving outcomes in the field of cell therapy.
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.
AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, founded in 2017. The company is dedicated to the research, development, and commercialization of innovative medicines aimed at addressing infectious diseases. AN2 Therapeutics is focused on developing epetraborole, a once-daily oral treatment for patients suffering from chronic non-tuberculous mycobacterial lung disease, which represents a significant unmet medical need. Additionally, the company has established a strategic partnership with Brii Biosciences to enhance its development efforts.
ADARx Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on the research and development of RNA editing therapeutics. Founded in 2019, the company specializes in the precise targeting and correction of single point mutations on mRNA transcripts using a proprietary platform that leverages endogenous enzymes known as adenosine deaminase acting on RNA (ADAR). This innovative approach aims to restore the production of functional proteins, addressing genetic mutations that lead to various diseases. ADARx Pharmaceuticals is developing a diverse pipeline of ribonucleic acid targeting therapeutics aimed at treating conditions across multiple therapeutic areas, including genetic disorders, cardiometabolic diseases, complement-mediated diseases, and central nervous system disorders.
InspireMD, Inc. is a medical device company headquartered in Tel Aviv, Israel, specializing in the development and commercialization of its proprietary MicroNet stent platform technology aimed at treating vascular and coronary diseases. The company offers the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection system, which is used in patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft interventions. InspireMD is also working on the NGuard, a neurovascular flow diverter intended to redirect blood flow from cerebral aneurysms. The company primarily generates revenue through the sale of its products via local distributors in various regions, including Europe, Latin America, the Middle East, and Asia.
Thunes, founded in 2016 and headquartered in Singapore, is a global B2B payment infrastructure platform that facilitates seamless cross-border payments for various businesses, including major players in the gig economy and fintech sectors. The platform supports transactions in 80 currencies across 132 countries and allows users to accept 300 different payment methods through a single connection. Thunes offers a range of services such as remittance processing, mass payouts, virtual accounts, and payment collection, utilizing application programming interfaces (APIs) to lower transaction fees and enhance interoperability among payment systems. In April 2022, the company acquired a controlling stake in Tookitaki, a compliance platform that bolsters Thunes' capabilities in anti-money laundering and fraud prevention. The company operates regional offices in major cities including London, Paris, and Dubai, and is backed by various investors, including Visa and Bessemer Venture Partners.
Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.
TRM Labs Inc. is a blockchain intelligence company that provides a token relationship management platform designed to assist financial institutions, cryptocurrency businesses, and government agencies in identifying and investigating financial crime and fraud related to digital assets. Founded in 2017 and headquartered in San Francisco, the company leverages machine learning to facilitate on-chain anti-money laundering compliance, incorporating solutions for customer due diligence, transaction monitoring, and relationship management. TRM Labs aims to enhance compliance within the cryptocurrency industry by developing tools that automatically detect suspicious activities, such as money laundering and market manipulation. The company has garnered significant investment from major financial institutions and is supported by a team of experts with backgrounds in law enforcement and top technology firms. TRM Labs operates as a remote-first organization with additional hubs in Washington, DC, and London.
VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in developing innovative treatments for severe rare diseases with significant unmet medical needs. Its primary product candidate, Apraglutide, is a long-acting synthetic analog of glucagon-like peptide-2 (GLP-2) designed to enhance the intestine's ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support. VectivBio aims to deliver transformational therapies that significantly improve the lives of patients and their families, rather than offering only incremental benefits over existing treatments.
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Neurolens is a company that specializes in prescription lenses designed to alleviate discomfort caused by eye misalignment. Founded in 2012 and based in Costa Mesa, California, Neurolens incorporates a contoured prism into its lenses to improve eye alignment, which can help relieve headaches, neck and shoulder pain, and eyestrain. The company has developed a vision measurement device that utilizes an eye-tracking system capable of detecting even minor misalignments, measured in prism diopters. This innovative approach aims to address the chronic discomfort many individuals experience due to prolonged use of digital devices, reading, or engaging in detailed work.
Amun is a token provider that aims to simplify access to decentralized finance (DeFi) and cryptocurrency investments. The company offers a range of exchange-traded products (ETPs) that allow investors to engage with cryptocurrency assets as easily as purchasing stocks. Amun's platform features a diversified, market-cap weighted basket of the top five cryptocurrencies, which is automatically rebalanced to reflect current market conditions. This enables investors to track the financial performance of these assets effectively, ensuring a clear representation of the evolving cryptocurrency market. Through its innovative approach, Amun seeks to make crypto investing more accessible and secure for a broader audience.
21.co is a cryptocurrency company providing access to crypto through simple and easy-to-use products. 21.co is the parent company of 21Shares, the world’s largest issuer of cryptocurrency exchange-traded products (ETPs) – which is powered by Onyx, a proprietary technology platform used to issue and operate cryptocurrency ETPs for 21Shares and third parties – in addition to Amun, a token provider focused on making the Defi world more accessible. The company was founded in 2018 by Hany Rashwan and Ophelia Snyder. 21.co is registered in Zug, Switzerland with offices in Zurich and New York.
Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on advancing drug delivery methods to enhance patient experiences. Established in 2016, the company has developed a formulation system capable of processing a diverse array of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. Its innovative technology aims to improve subcutaneous administration, allowing drug manufacturers to create breakthrough therapies that empower patients with more control over how they receive essential medications.
Turtlemint is an online insurance platform founded in 2015 and headquartered in Mumbai, Maharashtra, India. The platform simplifies the insurance purchasing process by providing clear explanations of complex terms and offering smart tools to assist users in selecting suitable insurance policies. Turtlemint specializes in various types of insurance, including car, bike, health, and term life insurance. Utilizing proprietary algorithms and data analytics, the platform generates tailored recommendations for consumers. Additionally, Turtlemint maintains a network of offline facilitators to assist clients in completing purchases and navigating claims, ensuring a comprehensive support system for users throughout their insurance journey.
Private Equity Round in 2022
Circle is a financial technology firm that leverages blockchain technology and stablecoins to facilitate payments and e-commerce. Founded in 2013 by Jeremy Allaire and Sean Neville, Circle enhances the way users send and receive money through its platform, Circle Pay. The company offers a cryptocurrency investment product called Circle Invest, enabling users to buy and sell various crypto assets. Additionally, Circle provides over-the-counter trading services through Circle Trade, featuring one of the largest global liquidity pools for digital asset trading, with an average monthly volume of $2 billion. Backed by significant investments from notable firms, Circle operates from its headquarters in Boston and has branches in New York, San Francisco, Dublin, London, and Hong Kong.
Parse Biosciences is a biotechnology startup based in Seattle, Washington, that specializes in single-cell analysis. Founded in 2018 and rebranded from Split Biosciences in 2020, the company has developed innovative single-cell sequencing kit solutions that utilize combinatorial cDNA barcoding. This technology allows researchers to conduct experiments without the need for complex and costly microfluidic instruments. It also enables the fixation, freezing, and storage of samples, which separates sample extraction from downstream library preparation steps. As a result, researchers can analyze fixed samples collected on different dates in a single experiment, enhancing control over sample handling and minimizing errors. Additionally, Parse Biosciences’ technology improves gene detection in individual cells while reducing common confounding artifacts in single-cell sequencing, making it a valuable resource for researchers in the field.
Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.
Lukka, Inc. is a blockchain-native technology company based in New York that provides middle and back office solutions tailored for the crypto-asset ecosystem. Established in 2014, Lukka specializes in managing and processing complex blockchain and cryptocurrency data, delivering tools that enhance accounting, auditing, tax reporting, and compliance for various entities, including funds and exchanges. Its key offerings include LukkaTax, which simplifies tax calculations for cryptocurrency transactions, and LukkaCrypto Office, a back-office solution designed to manage crypto assets with features for pricing, valuation, and reporting. Additionally, Lukka Reference Data provides normalized data for crypto assets, ensuring consistency and accuracy for enterprise applications. The company's solutions facilitate real-time visibility into crypto transaction activities, helping institutions meet their reporting and compliance needs efficiently.
Private Equity Round in 2022
Accelerant is a technology-driven insurtech company that provides insurance underwriting services primarily for small and medium-sized businesses. It specializes in property and casualty insurance products through a full-service risk exchange that connects a carefully selected network of underwriting teams. By leveraging advanced data analytics, Accelerant offers underwriters enhanced insights into risk management and insurance pools, ensuring a diversified portfolio with minimal exposure to catastrophe and systemic risks. The company has received an AM Best A- (Excellent) rating, reflecting its commitment to financial stability and excellence in service.
Tipalti, Inc. is a company that specializes in accounts payable automation and global mass payments software. Founded in 2010 and headquartered in San Mateo, California, with an additional office in Kibbutz Glil-Yam, Israel, Tipalti's platform streamlines the payment process for businesses by automating various tasks such as invoice processing, supplier management, and payment reconciliation. The software supports features like tax compliance and global funds disbursement, allowing companies to efficiently manage payments to suppliers, partners, and affiliates. By implementing Tipalti's solution, organizations can reduce their supplier payment workload significantly, enabling them to focus on scaling their operations while maintaining compliance and improving financial controls. The company serves a diverse range of industries, including ad networks, ecommerce, online marketplaces, and video content providers.
TRM Labs Inc. is a blockchain intelligence company that provides a token relationship management platform designed to assist financial institutions, cryptocurrency businesses, and government agencies in identifying and investigating financial crime and fraud related to digital assets. Founded in 2017 and headquartered in San Francisco, the company leverages machine learning to facilitate on-chain anti-money laundering compliance, incorporating solutions for customer due diligence, transaction monitoring, and relationship management. TRM Labs aims to enhance compliance within the cryptocurrency industry by developing tools that automatically detect suspicious activities, such as money laundering and market manipulation. The company has garnered significant investment from major financial institutions and is supported by a team of experts with backgrounds in law enforcement and top technology firms. TRM Labs operates as a remote-first organization with additional hubs in Washington, DC, and London.
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing therapeutics that target challenging cancer types without straightforward single-gene mutations. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments. Acrivon's pipeline includes ACR-368, also known as prexasertib, which is currently in Phase 2 trials, alongside preclinical programs aimed at key components of DNA damage response and cell cycle regulation, such as the WEE1 and PKMYT1 proteins. Acrivon seeks to expedite the development of both in-licensed clinical-stage assets and its internally developed programs through accelerated registration trials, aiming to enhance treatment success in oncology.
CRED is a members-only application that incentivizes users by offering exclusive rewards for timely credit card bill payments. The platform promotes financial responsibility by encouraging users to maintain good credit scores while rewarding them with various offers and discounts on shopping, health services, and other expenditures. CRED prioritizes the protection of user data through stringent security processes and compliance with regulatory standards, ensuring transparency and opt-in consent for data usage. By facilitating on-time credit card payments, CRED not only helps users manage their finances better but also enhances their overall spending experience with valuable rewards.
Varo Money is driven by a mission to redefine banking so it’s easy for everyone to make smart choices with their money. In one mobile app, Varo offers customers no-cost premium bank accounts and high-interest savings accounts offered through The Bancorp Bank, and tech-first features to help people manage their money more easily. The company was founded in 2015 and is headquartered in San Francisco, California.
Inbrace is a medical device company focused on innovative orthodontic solutions. Its flagship product, INBRACE, is a discreet alignment system that is placed behind the teeth, utilizing patented self-guiding technology to apply continuous forces for gentle correction of dental alignment. This approach significantly reduces pain and minimizes the number of required visits to the orthodontist, addressing common patient concerns and enhancing satisfaction. INBRACE is FDA registered and aims to expand access to orthodontic treatment, thereby driving practice growth for dental professionals. The company's platform incorporates digital treatment planning, computer modeling, and direct digital manufacturing, allowing for customized solutions that maintain high standards of care across various orthodontic cases.
Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.
Neurogastrx, Inc. is a venture-stage biopharmaceutical company developing products for the treatment of gastrointestinal disorders.
Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.
Private Equity Round in 2021
Circle is a financial technology firm that leverages blockchain technology and stablecoins to facilitate payments and e-commerce. Founded in 2013 by Jeremy Allaire and Sean Neville, Circle enhances the way users send and receive money through its platform, Circle Pay. The company offers a cryptocurrency investment product called Circle Invest, enabling users to buy and sell various crypto assets. Additionally, Circle provides over-the-counter trading services through Circle Trade, featuring one of the largest global liquidity pools for digital asset trading, with an average monthly volume of $2 billion. Backed by significant investments from notable firms, Circle operates from its headquarters in Boston and has branches in New York, San Francisco, Dublin, London, and Hong Kong.
Pine Labs operates a merchant platform that provides technology and financial solutions aimed at enhancing revenue for merchants while minimizing costs, complexity, and risk. The company connects financial institutions and consumer brands, facilitating both offline and online retail transactions. Pine Labs powers over 350,000 point-of-sale terminals across more than 3,700 cities and towns in India and Malaysia, serving over 100,000 merchants in various sectors, including electronics, food and beverage, and fashion. Its platform also offers customer insights to drive targeted sales and streamline payment acceptance through features like easy monthly installments (EMI) across multiple banks and product categories. Additionally, Pine Labs collaborates with 15 major banks, seven financial institutions, and more than 100 brands to enhance the retail experience for both merchants and consumers.
Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. The company partners with innovators in the gene therapy community: scientists, physicians, biotech/pharma companies, and patient groups. It was founded in 2020 and headquartered in Grove City, Ohio.
Exscientia is a company that applies artificial intelligence and machine learning to the discovery and design of new therapeutic compounds. By combining human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to create safer and more effective treatments for clinical testing. The company focuses on precision engineering of medicine candidates, utilizing innovative experimental methods to enhance drug discovery processes. Through these efforts, Exscientia strives to improve patient outcomes and transform the pharmaceutical industry.
Century Therapeutics is a biotechnology company focused on developing advanced cell therapies using induced pluripotent stem cells (iPSCs) to treat various cancers, including hematologic and solid tumors. Founded in 2018 and based in Philadelphia, Pennsylvania, the company utilizes a unique allogeneic iPSC-derived cell therapy platform that integrates gene editing, protein engineering, and robust manufacturing capabilities. This innovative approach allows for the generation of modified immune effector cells, such as natural killer (NK) and T cells, designed to meet significant unmet medical needs. By employing techniques like CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to enhance cell product performance and minimize rejection by the host immune system, thereby improving the efficacy of cancer treatments.
International Airlines Group (IAG) is one of the largest airline groups globally, primarily engaged in the transportation of passengers and cargo. It operates multiple well-known subsidiaries, including British Airways, Iberia, Vueling, and Aer Lingus, which maintain their distinct brands while benefiting from the group's combined resources. IAG's main airport hubs are located in London, Madrid, Barcelona, and Dublin, allowing it to enhance its global presence. The group's revenue is predominantly generated from the United Kingdom, with significant contributions also from Spain, the United States, and other international markets. Each airline within the group is managed as a separate operating company, facilitating tailored strategies and resource allocation.
LGI Homes, Inc. specializes in the design, construction, and sale of new homes throughout the United States. Founded in 2003 and headquartered in The Woodlands, Texas, the company provides a range of housing options, including entry-level homes, move-up homes, and luxury series homes under its Terrata Homes brand. LGI Homes offers a variety of floor plans and customizable features, such as granite countertops and ceramic tile flooring. Operating across multiple states, the company serves markets in Texas, Arizona, Florida, Georgia, New Mexico, Colorado, North Carolina, South Carolina, Washington, Tennessee, Minnesota, Oklahoma, Alabama, California, Oregon, Nevada, and West Virginia. As of March 2020, LGI Homes owned 113 communities, reflecting its significant presence in the residential real estate sector.